Skip to main content

Category

Glp 1

7 articles

childhood obesityhealth policy

Childhood Obesity in Australia: Why Individual Responsibility Framing Has Failed and What Policy Must Change

One in four Australian children is overweight or obese. A policy analysis of why 'eat less, move more' campaigns fail, and what evidence-based interventions — sugar taxes, advertising bans, food labelling reform, and school food environments — can actually work.

24 May 202612 min read
type 2 diabetesAustralia

Type 2 Diabetes in Australia: Prevalence, Cost and Policy

Type 2 diabetes Australia statistics: 1.2 million diagnosed, $4.4 billion in annual health expenditure, and deep equity gaps demanding urgent policy reform.

12 May 202610 min read
weight stigmahealth policy

Weight Stigma in Australian Healthcare: Evidence and Policy

How weight stigma in Australian healthcare policy deters care, drives worse outcomes, and what clinician bias training and GLP-1 era reframing can change.

5 May 202610 min read
bariatric surgeryobesity

Bariatric Surgery Access in Australia: Policy Failures, Equity Gaps, and the Case for Reform

Australia's bariatric surgery system is two-tiered, inequitable, and failing hundreds of thousands of people with severe obesity. A policy analysis of access barriers, public waitlist failures, the economic case for expanded funding, and the role of GLP-1 medications in reshaping the surgical pipeline.

10 Apr 202621 min read
GLP-1semaglutide

GLP-1 Medication Shortage in Australia: Policy Failures, Access Inequity, and the Path to Reform

Australia's GLP-1 receptor agonist shortage exposes deep structural failures in medicines policy. This analysis examines the supply crisis, access inequities, the compounding pharmacy debate, and six concrete reforms needed to ensure equitable access to life-changing obesity and diabetes treatments.

26 Mar 202613 min read
PBSobesity

Medicare and PBS Reform for Obesity Treatment: What Australia Needs to Do

Australia's PBS coverage of obesity medications is inadequate, inequitable, and out of step with the clinical evidence. A policy analysis of the case for expanded PBS listing of GLP-1 receptor agonists and what reform should look like.

7 Mar 202618 min read
metabolic syndromeAustralia

Metabolic Syndrome in Australia: The Policy Gap Between Evidence and Action

Australia's metabolic syndrome burden is large, growing, and poorly addressed by current Medicare and public health policy. An evidence-based analysis of the gap between what the research shows and what the health system delivers.

6 Mar 202619 min read